To that end, we compared the effects of gemcitabine plus cisplatin (GC regimen) and BEZ/GSK/TSA treatment (BGT regimen) on NSCLC and CRC cell lines carrying wild-type or mutant KRAS alleles. Here, KRAS is linked to non-small cell lung carcinoma.